Retina
- Address
- lock Available on a paid plan
Age‑Related Macular Degeneration Research
The Retina site in Saint‑Cyr‑Sur‑Loire concentrates on age‑related macular degeneration, addressing both its neovascular and dry forms.
- Neovascular AMD treatment evaluation
- Geographic atrophy progression studies
- Long‑term safety of complement‑inhibiting agents
- Oral therapies aimed at slowing atrophy
Ongoing trials aim to test new intravitreal drugs and oral compounds to preserve vision and assess extended safety profiles.
Diabetic Eye Disease Studies
Researchers at the Retina clinic are investigating innovative options for diabetic macular edema.
- Comparison of novel intravitreal agents with standard anti‑VEGF therapy
- Visual acuity outcomes measured by ETDRS charts
- Safety monitoring over a 12‑month period
The purpose is to determine whether emerging treatments can match or exceed current standards in improving sight for diabetic patients.
Myopia‑Related Neovascular Conditions
The center conducts trials on choroidal neovascularization secondary to pathologic myopia.
- Efficacy of intravitreal therapies in myopic CNV
- Improvement in best‑corrected visual acuity
- Safety and tolerability assessments
These studies seek effective options to reduce vision loss caused by myopia‑driven neovascular disease.
Complement Pathway Inhibition in Geographic Atrophy
Focused investigations target the complement system for treating geographic atrophy linked to AMD.
- Long‑term safety of pegcetacoplan injections
- Avacincaptad pegol monthly administration outcomes
- Dose‑response analysis of investigational complement inhibitors
Trials assess whether blocking complement activation can slow lesion expansion and preserve retinal function.
Oral Neuroprotective Strategies
The site evaluates systemic agents such as dimethyl fumarate for their potential to curb geographic atrophy progression.
- Efficacy of oral dimethyl fumarate versus standard care
- Impact on geographic atrophy lesion area over 12 months
- Safety profile of sustained oral dosing
The goal is to explore convenient, non‑invasive treatments that may complement intravitreal therapies in preserving vision.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Eyebiotech Limited1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eyebiotech Limited3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Retina
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 9 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Fluorescein Sodium | 5 | Unknown | 2022-12-21 | 2026-06-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.